Patents by Inventor David Stefany
David Stefany has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9533995Abstract: The present disclosure relates to a series of substituted N-heteroaryl spirolactam bipyrrolidines of formula (I). Wherein R1, R2, Q1, Q2, Q3, Q4, X, m, n, p and s are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this disclosure also relates to methods of preparation of substituted N-heteroaryl spirolactam bipyrrolidines of formula (I) and intermediates therefor.Type: GrantFiled: June 27, 2014Date of Patent: January 3, 2017Assignee: SanofiInventors: Zhongli Gao, Daniel Hall, David Stefany
-
Publication number: 20140315923Abstract: The present disclosure relates to a series of substituted N-heteroaryl spirolactam bipyrrolidines of formula (I). Wherein R1, R2, Q1, Q2, Q3, Q4, X, m, n, p and s are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this disclosure also relates to methods of preparation of substituted N-heteroaryl spirolactam bipyrrolidines of formula (I) and intermediates therefor.Type: ApplicationFiled: June 27, 2014Publication date: October 23, 2014Inventors: Zhongli GAO, Daniel HALL, David STEFANY
-
Patent number: 8859588Abstract: The present disclosure relates to a series of substituted N-heteroaryl bipyrrolidine carboxamides of formula (I). wherein R1, R2, R3, R4, Q1, Q2, Q3, Q4, X, m and p are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this disclosure also relates to methods of preparation of substituted N-heteroaryl bipyrrolidine carboxamides of formula (I) and intermediates therefor.Type: GrantFiled: November 6, 2012Date of Patent: October 14, 2014Assignee: SanofiInventors: Zhongli Gao, Daniel Hall, David Stefany
-
Patent number: 8796278Abstract: The present disclosure relates to a series of substituted N-heteroaryl spirolactam bipyrrolidines of formula (I). Wherein R1, R2, Q1, Q2, Q3, Q4, X, m, n, p and s are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this disclosure also relates to methods of preparation of substituted N-heteroaryl spirolactam bipyrrolidines of formula (I) and intermediates therefor.Type: GrantFiled: November 6, 2012Date of Patent: August 5, 2014Assignee: SanofiInventors: Zhongli Gao, Daniel Hall, David Stefany
-
Patent number: 8383814Abstract: The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I): wherein R1, R2, m, n and p are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefore are disclosed.Type: GrantFiled: May 30, 2012Date of Patent: February 26, 2013Assignee: SanofiInventors: Zhongli Gao, Ryan Hartung, David Stefany
-
Publication number: 20130005728Abstract: The present invention is directed to a substituted pyrimidine compound of formula (I) or an enantiomer thereof, or a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Keith J. HARRIS, Joacy C. AGUIAR, Patrick Wai-Kwok SHUM, Zhicheng ZHAO, Gregory B. POLI, Gregory STOKLOSA, Yong-Mi CHOI-SLEDESKI, Stephan REILING, David STEFANY, Charles GARDNER
-
Publication number: 20120238757Abstract: The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I): wherein R1, R2, m, n and p are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefore are disclosed.Type: ApplicationFiled: May 30, 2012Publication date: September 20, 2012Applicant: SANOFIInventors: Zhongli GAO, Ryan HARTUNG, David STEFANY
-
Patent number: 8217052Abstract: The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I): wherein R1, R2, m, n and p are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefore are disclosed.Type: GrantFiled: June 2, 2011Date of Patent: July 10, 2012Assignee: SanofiInventors: Zhongli Gao, Ryan Hartung, David Stefany
-
Patent number: 8193183Abstract: The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemType: GrantFiled: April 16, 2007Date of Patent: June 5, 2012Assignee: Aventis Pharmaceuticals Inc.Inventors: Sungtaek Lim, Keith John Harris, David Stefany, Charles J. Gardner, Bin Cao, Ray Boffey, Timothy A. Gillespy, Joacy C. Aguiar, Hazel J. Dyke, Elsa A. Dechaux
-
Publication number: 20110251225Abstract: The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I): wherein R1, R2, m, n and p are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefore are disclosed.Type: ApplicationFiled: June 2, 2011Publication date: October 13, 2011Applicant: SANOFIInventors: Zhongli GAO, Ryan HARTUNG, David STEFANY
-
Publication number: 20090036469Abstract: The present invention is directed to a compound of formula (I), wherein R1 and R2 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds of the invention in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder by administering to said patient a pharmaceutically effective amount of a compound of the invention.Type: ApplicationFiled: October 7, 2008Publication date: February 5, 2009Applicant: SANOFI-AVENTISInventors: David STEFANY, Keith John HARRIS, Timothy Alan GILLESPY, Charles J. GARDNER, Joacy C. AGUIAR
-
Publication number: 20070244131Abstract: The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischeType: ApplicationFiled: April 16, 2007Publication date: October 18, 2007Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Sungtaek Lim, Keith Harris, David Stefany, Charles Gardner, Bin Cao, Ray Boffey, Timothy Gillespy, Joacy Aguiar, Hazel Dyke, Elsa Dechaux
-
Publication number: 20070032489Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.Type: ApplicationFiled: September 26, 2006Publication date: February 8, 2007Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Philip Weintraub, Paul Eastwood, Shujaath Mehdi, David Stefany, Kwon Musick, Neil Moorcroft, Sungtaek Lim, John Jiang, Hartmut Rutten, Stefan Peukert, Uwe Schwahn